06/05/2025 | Press release | Distributed by Public on 06/05/2025 06:31
Item 8.01 Other Events.
As previously reported on the Current Report on Form 8-K of Aethlon Medical, Inc. (the "Company"), as filed with the Securities and Exchange Commission on May 13, 2025, at the Company's Special Meeting of Stockholders held on May 13, 2025 (the "Special Meeting"), the Company's stockholders approved, pursuant to Nevada Revised Statutes ("NRS") 78.2055, a reverse stock split of the Company's common stock at a ratio in the range of 1-for-5 to 1-for-12, with such ratio to be determined in the discretion of the Company's Board of Directors (the "Board") and with such reverse stock split to be effected at such time and date as determined by the Board in its sole discretion (but in no event later than May 13, 2026). Following the Special Meeting on May 13, 2025, the Board unanimously approved, pursuant to NRS 78.2055, a reverse stock split of all issued and outstanding shares of the Company's common stock, at a ratio of 1-for-8 (the "Reverse Stock Split"). The Reverse Stock Split will be implemented at 5:00 p.m. Eastern Time on June 6, 2025 (the "Effective Time") with trading commencing upon market opening on June 9, 2025.
The terms of the Reverse Stock Split are such that every eight shares of the Company's issued and outstanding common stock will automatically be combined into one issued and outstanding share of common stock, without any change in par value per share. As a result of the Reverse Stock Split, proportionate adjustments will be made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, restricted stock units and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, restricted stock units and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the Effective Time will be reduced proportionately.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders will be issued one whole share of common stock in exchange for any fractional interest that such stockholder would have otherwise received as a result of the Reverse Stock Split. The Reverse Stock Split will affect all stockholders proportionately and will not affect any stockholder's percentage ownership of the Company's common stock, except to the extent that the Reverse Stock Split results in any stockholder owning an additional share.
The Company's common stock will begin trading on a split-adjusted basis commencing upon market opening on The Nasdaq Capital Market on June 9, 2025. The new CUSIP number for the Company's common stock following the Reverse Stock Split is 00808Y 505.